
Please try another search
SAN DIEGO - Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology firm specializing in immunotherapies, has announced its return to compliance with Nasdaq's listing requirements. The company...
Cidara Therapeutics, Inc. (Nasdaq: NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and...
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- WHY: New York, N.Y., May 14, 2024. Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf...
SAN DIEGO, April 26, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC)...
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cidara Therapeutics...
On Thursday, Needham raised the price target on shares of Cidara Therapeutics (NASDAQ:CDTX) to $25.00, a significant increase from the previous target of $3.00. The investment firm maintained its Buy...
SAN DIEGO - Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company specializing in drug-Fc conjugate immunotherapies, announced today the sale of its antifungal drug, rezafungin, to...
Investing.com - Cidara Therapeutics Inc (NASDAQ: CDTX) reported first quarter EPS of $-0.040, $0.06 better than the analyst estimate of $-0.103. Revenue for the quarter came in at $17.58M versus the...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review